New York, June 12, 2026, 13:50 (ET)
- CUPR surged after Cuprina said Nasdaq told the company it is back in line with listing requirements.
- There’s no more immediate delisting hearing risk, though this comes after a 1-for-8 reverse split.
- The next question is if Cuprina can get commercial traction in chronic wound care and other biomedical markets.
Cuprina Holdings (Cayman) Limited shares jumped Friday after the biomedical firm said it is back in line with Nasdaq Capital Market rules, easing delisting worries. The Singapore-based company’s Nasdaq-listed stock was recently at $4.20, up roughly 74% from the previous close, and traded between $2.33 and $7.91 in heavy volume, with about 79.3 million shares changing hands.
Cuprina’s June 12 filing said Nasdaq staff told the exchange’s hearings department the company is back in compliance with the minimum bid price rule. That rule requires primary securities on the Nasdaq Capital Market to keep a $1.00 minimum bid. Cuprina had missed compliance by May 26, asked for a hearing two days later, and now says the July 7 hearing is cancelled.
That’s an issue for the stock because delisting risk can hit liquidity and keep out institutional buyers, sending speculators into already thin micro-cap trading. The compliance news came after Cuprina’s 1-for-8 share consolidation. This reverse split bundled every eight shares into one, usually lifting the share price but not changing the business. Cuprina said in May the move aimed to get back above the Nasdaq’s bid-price rule, with CEO David Quek calling it “an important step toward maintaining our Nasdaq listing.” GlobeNewswire
Cuprina jumped Friday, but there was no new sales or profit news. In its latest annual filing with the SEC, the company put 2025 revenue at S$49,894, or US$38,789. Net loss deepened to S$4.67 million, or US$3.63 million. Cash and cash equivalents stood at S$3.12 million, or US$2.42 million, as of Dec. 31, 2025.
Cuprina works in biomedical and biotech, with products like MEDIFLY, a sterile blowfly larvae for maggot debridement therapy—used to clear dead tissue from chronic wounds. Reuters has Cuprina listed under chronic wound care and health and beauty, with business in maggot therapy and cosmeceuticals.
Nasdaq compliance could give Cuprina more time to work on its growth plans without the immediate risk of a hearing over its listing. Investors are likely watching for results—whether business milestones start to bring in revenue, including the company’s March update that its 49%-owned Cuprina MENA secured Saudi Food and Drug Authority product classification for MEDIFLY as a Medical Device–Drug combination product. Cuprina said that approval lets it finish the steps needed for commercial distribution in Saudi Arabia.
Bears argue the stock is running on speculation. The company’s real financial footing is still limited, losses stack up against its revenue, and the share consolidation just patched up the listing-price issue instead of addressing how the business runs. Cuprina flagged in its annual report that raising more capital could dilute shareholders if it issues extra equity, so current holders could see their ownership shrink.
CUPR is trading as a risky bet based on facts out today. The Nasdaq compliance update helps trading continue—CEO David Quek said Friday, “We are gratified to regain compliance with Nasdaq,” and said the company wants to grow in biomedical. Still, the stock saw a sharp price jump, big intraday swings, and hasn’t shown much revenue. The real test isn’t the cancelled hearing. The next big move will be if Cuprina can hit regulatory and product milestones that actually lift sales and cut losses. GlobeNewswire
